Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04190654 · ClinicalTrials.gov registry record · Phase 1
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
A Phase 1 study, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT04190654 is a Phase 1 study that has completed, run by Kyowa Kirin. The registered enrollment target is 26 participants.
The verdict
NCT04190654, a Phase 1 study, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, single-dose study to investigate the plasma PK of KW-6356 and its major metabolite, after a single oral dose of KW-6356, in subjects with mild or moderate hepatic impairment and in healthy adults
Interventions
- DRUG KW-6356
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-11-26 |
| Est. Completion | 2020-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04190654
The ClinicalTrials.gov registry entry for NCT04190654 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KW-6356 is the first listed.
NCT04190654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04190654 about?
NCT04190654 is a clinical study titled "Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite". This is an open-label, non-randomized, single-dose study to investigate the plasma PK of KW-6356 and its major metabolite, after a single oral dose of KW-6356, in subjects with mild or moderate hepatic impairment and in healthy adults
What is the current status of trial NCT04190654?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2019-11-26. Estimated completion is 2020-03-20.
What interventions are being tested in trial NCT04190654?
The interventions under investigation include: KW-6356 (DRUG).
Who is sponsoring clinical trial NCT04190654?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.